Tracked forImpact Factor
Indexed inScopus
22 daysTime to First Decision

Pharmacoepidemiology, Volume 4, Issue 4

December 2025 - 3 articles

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (3)

Select all

Review

19 Pages

Antimicrobial Resistance in Immunocompromised Outpatients: A Narrative Review of Current Evidence and Challenges

Farhood Sadeghi,
Erta Rajabi,
Zahra Ghanbari,
Sajjad Fattahniya,
Reza Samiee,
Mandana Akhavan,
Mohammadreza Salehi and
Maryam Shafaati

Pharmacoepidemiology2025, 4(4), 21;https://doi.org/10.3390/pharma4040021

3 October 2025

Immunocompromised outpatients, including people living with HIV/AIDS (PLWH), diabetes, cancer, and organ transplant recipients, are at high risk of antimicrobial resistance (AMR) due to their weakened immune systems and use of immunosuppressive thera...

Full Article

Article

14 Pages

Factors Associated with Suboptimal Adherence to Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma—A Retrospective Cohort Study

Fiona Angus,
Jingkun Sun,
Wan-Chuen Liao,
Arfan Khan and
Li-Chia Chen

Pharmacoepidemiology2025, 4(4), 20;https://doi.org/10.3390/pharma4040020

3 October 2025

Background: Adherence to tyrosine kinase inhibitors (TKIs), the first-line treatment for renal cell carcinoma (RCC), is critical to ensure intended treatment outcomes. However, 75% of patients with RCC have persistency gaps (>7 days) within the fi...

Full Article

Article

13 Pages

Fact-Finding Survey of Lethal or Fatal Adverse Drug Events in the Japanese Adverse Drug Event Report Database, Fiscal Year 2004–2023 (Adults ≥ 20 Years)

Hiroyuki Tanaka and
Toshihiro Ishii

Pharmacoepidemiology2025, 4(4), 19;https://doi.org/10.3390/pharma4040019

26 September 2025

Background: While adverse drug events (ADEs) are a major public health concern, data on the occurrence of lethal or fatal ADEs in Japan are limited. Therefore, this study aimed to elucidate the characteristics and reporting trends of lethal or fatal...

Full Article